Kays Medical

Activities: Training & Education Design & Build Manufacturing Hi Tech Manufacturing Regulatory Active Nutrition Food

Trending Articles

  1. Johnson & Johnson to bolster neuroscience portfolio with $14.6bn Intra-Cellular Therapies acquisition Through this potential acquisition, Johnson & Johnson will add schizophrenia and bipolar drug Caplyta to its portfolio, as well as a range of clinical candidates designed to...
  2. Lonza and Iconovo collaborate to develop intranasal biologic for obesity The two will aim to create an effective and stable inhaled formulation that can be used to treat obesity without the need for frequent injections
  3. Teva Pharmaceuticals, Klinge Pharma and Formycon join forces to commercialise Eylea biosimilar FYB203, which will be marketed under the name AHZANTIVE®3 if approved by the EMA, will be commercialised by Teva Pharmaceuticals in the majority of Europe and Israel
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Revolutionising drug delivery and advancing sustainability Capsule innovation and 3D printing will transform pharma for a future of precision and ethical solutions
  5. MM Pharma showcases its secondary packaging solutions at Pharmapack Europe 2025 Visitors to booth J85 can chat with technical experts about pharmaceutical packaging challenges and requirements, as well as how MM Pharma can help with their secondary...

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Design & Build

Safety advice for chemical splashes questioned

Study suggests safety data stating water should be used on eyes for chemical splashes is misleading
Subscribe now